Advertisement

Prevention of Ovarian Cancer

  • Sarika Gupta
  • Sarfraz Ahmad
  • Lorna A. Brudie
Chapter

Abstract

Prevention of ovarian cancer is critical in reducing the mortality and morbidity for patients with ovarian cancer. Growing evidence suggests that primary and secondary prevention of ovarian cancer in women with average risk do not confer mortality benefits. Primary surgical prevention through risk-reducing salpingo-oophorectomy is the most effective way of preventing ovarian cancer. This chapter focuses on the assessment of genetic and nongenetic risk factors for ovarian cancer that eventually guide surgical prevention and chemoprophylaxis in women with high-risk disease. It is emphasized that adequate family history and appropriate genetic counseling referral by the physicians is the key to recommend surgical or medical prevention for ovarian cancer. Recent insights into the site of precursor lesion and natural history of the disease have suggested that significant proportion of aggressive ovarian cancer originates as a premalignant lesion in the fallopian tube, making bilateral salpingectomy as a potential preventative option for a group of women requesting short-term ovarian preservation.

Keywords

Ovarian cancer Prevention of ovarian cancer Screening Risk factors for ovarian cancer Risk assessment models of ovarian cancer Genetic susceptibility to ovarian cancer Risk-reducing salpingo-oophorectomy Surgical prevention/intervention Nonsurgical risk reduction of ovarian cancer Hereditary ovarian cancer BRCA1/BRCA2 testing Peer-reviewed literature summary/update 

References

  1. 1.
    Hemminki K, Sundquist J, Brandt A. Incidence and mortality in epithelial ovarian cancer by family history of any cancer. Cancer. 2011;117(17):3972–80.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992;136(10):1184–203.CrossRefGoogle Scholar
  3. 3.
    Giannakeas V, Sopik V, Shestopaloff K, Iqbal J, Rosen B, Akbari M, et al. A model for estimating ovarian cancer risk: application for preventive oophorectomy. Gynecol Oncol. 2015;139(2):242–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Brekelmans CTM. Risk factors and risk reduction of breast and ovarian cancer: current opinion in obstetrics and gynecology. Curr Opin Obstet Gynecol. 2003;15(1):63–8.PubMedCrossRefGoogle Scholar
  5. 5.
    McAlpine JN, Hanley GE, Woo MMM, Tone AA, Rozenberg N, Swenerton KD, et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol. 2014;210(5):471.e1.CrossRefGoogle Scholar
  6. 6.
    Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, et al. Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. J Clin Oncol. 2016;34(24):2888–98.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Narod SA. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. J Am Med Assoc. 2006;296(2):185–92.CrossRefGoogle Scholar
  8. 8.
    Scully RE. Early de novo ovarian cancer and cancer developing in benign ovarian lesions. Int J Gynecol Obstet. 1995;49(suppl):S9–15.CrossRefGoogle Scholar
  9. 9.
    Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol. 1999;72:437–42.PubMedCrossRefGoogle Scholar
  10. 10.
    Colgan TJ, Murphy J, Cole DEC, Narod S, Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 2001;25(10):1283–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Piek JMJ, Van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJJ, Menko FH, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195(4):451–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol. 2002;87(1):52–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31(2):161–9.PubMedCrossRefGoogle Scholar
  14. 14.
    McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43:420–32.PubMedCrossRefGoogle Scholar
  15. 15.
    Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, et al. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Arch Gynecol Obstet. 2016;293(4):695–700.PubMedCrossRefGoogle Scholar
  16. 16.
    Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34(3):433–43.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Bethesda M. SEER cancer statistics fact sheet: ovary cancer. SEER. 2014. Retrieved from https://seer.cancer.gov/archive/csr/1975_2014/
  18. 18.
    Grossman DC, Curry SJ, Owens DK, Barry MJ, Davidson KW, Doubeni CA, et al. Screening for ovarian cancer. JAMA. 2018;319(6):588.PubMedCrossRefGoogle Scholar
  19. 19.
    Hall MJ, Forman AD, Pilarski R, Wiesner G, Giri VN. Gene panel testing for inherited cancer risk. J Natl Compr Cancer Netw. 2014;12(9):1339–46.CrossRefGoogle Scholar
  20. 20.
    Kuchenbaecker KB, Hopper JLBD. Risk of breast, ovarian and contralateral breast cancer BRCA 1 and BRCA2 mutation carriers. JAMA. 2017;317:2402–16.PubMedCrossRefGoogle Scholar
  21. 21.
    Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015;313(13):1347–61.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2007;96:11–5.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329–33.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer. 2000;83(10):1301–8.PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Finch APM, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547–53.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Song H, Cicek MS, Dicks E, Harrington P, Ramus SJ, Cunningham JM, et al. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet. 2014;23(17):4703–9.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Watson P, Vasen HFA, Mecklin JP, Bernstein I, Aarnio M, Järvinen HJ, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer. 2008;123(2):444–9.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81(2):214–8.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010;42(5):410–4.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet. 2011;43(9):879–82.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Song H, Dicks E, Ramus SJ, Tyrer JP, Intermaggio MP, Hayward J, et al. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J Clin Oncol. 2015;33(26):2901–7.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Rafnar T, Gudbjartsson DF, Sulem P, Jonasdottir A, Sigurdsson A, Jonasdottir A, et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet. 2011;43(11):1104–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Ramus SJ, Song H, Dicks E, Tyrer JP, Rosenthal AN, Intermaggio MP, et al. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. J Natl Cancer Inst. 2015;107(11):djv214.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015;47(2):164–71.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017;49(5):680–91.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Thomas D. Gene-environment-wide association studies: emerging approaches. Nat Rev Genet. 2010;11:259–72.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402.PubMedCrossRefGoogle Scholar
  39. 39.
    Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(44):18032–7.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000;283(17):2260.PubMedCrossRefGoogle Scholar
  41. 41.
    Norquist BM, Pennington KP, Agnew KJ, Harrell MI, Pennil CC, Lee MK, et al. Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing. Gynecol Oncol. 2013;128(3):483–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Kwon JS, Daniels MS, Sun CC, Lu KH. Preventing future cancers by testing women with ovarian cancer for BRCA mutations. J Clin Oncol. 2010;28(4):675–82.PubMedCrossRefGoogle Scholar
  43. 43.
    Eccles DM, Balmaña J, Clune J, Ehlken B, Gohlke A, Hirst C, et al. Selecting patients with ovarian cancer for germline BRCA mutation testing: findings from guidelines and a systematic literature review. Adv Ther. 2016;33:129–50.PubMedCrossRefGoogle Scholar
  44. 44.
    Meyer LA, Anderson ME, Lacour RA, Suri A, Daniels MS, Urbauer DL, et al. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol. 2010;115(5):945–52.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Modesitt C, Lu Karen M. Practice bulletin no 182: hereditary breast and ovarian cancer syndrome. Obstet Gynecol. 2017;130(3):e110–26.CrossRefGoogle Scholar
  46. 46.
    Moyer VA. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. preventive services task force recommendation statement. Ann Intern Med. 2014;160(4):271–81.PubMedCrossRefGoogle Scholar
  47. 47.
    Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2015;17:70–87.PubMedCrossRefGoogle Scholar
  48. 48.
    Lu KH, Wood ME, Daniels M, Burke C, Ford J, Kauff ND, et al. American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. J Clin Oncol. 2014;32(8):833–40.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    McGee J, Panabaker K, Leonard S, Ainsworth P, Elit L, Shariff SZ. Genetics consultation rates following a diagnosis of high-grade serous ovarian carcinoma in the Canadian province of Ontario. Int J Gynecol Cancer. 2017;27(3):437–43.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Ricci MT, Sciallero S, Mammoliti S, Gismondi V, Franiuk M, Bruzzi P, et al. Referral of ovarian cancer patients for genetic counselling by oncologists: need for improvement. Public Health Genomics. 2015;18(4):225–32.PubMedCrossRefGoogle Scholar
  51. 51.
    Hoskins PJ, Gotlieb WH. Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: a review of the literature. CA Cancer J Clin. 2017;67(6):493–506.PubMedCrossRefGoogle Scholar
  52. 52.
    Sussner KM, Jandorf L, Thompson HS, Valdimarsdottir HB. Barriers and facilitators to BRCA genetic counseling among at-risk Latinas in New York City. Psychooncology. 2013;22(7):1594–604.PubMedCrossRefGoogle Scholar
  53. 53.
    Rosner BA, Colditz GA, Webb PM, Hankinson SE. Mathematical models of ovarian cancer incidence. Epidemiology. 2005;16(4):508–15.PubMedCrossRefGoogle Scholar
  54. 54.
    Li K, Hüsing A, Fortner RT, Tjønneland A, Hansen L, Dossus L, et al. An epidemiologic risk prediction model for ovarian cancer in Europe: the EPIC study. Br J Cancer. 2015;112(7):1257–65.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Pfeiffer RM, Park Y, Kreimer AR, Lacey JV, Pee D, Greenlee RT, et al. risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies. PLoS Med. 2013;10(7):e1001492.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Clyde MA, Palmieri Weber R, Iversen ES, Poole EM, Doherty JA, Goodman MT, et al. Risk prediction for epithelial ovarian cancer in 11 United States-based case-control studies: incorporation of epidemiologic risk factors and 17 confirmed genetic loci. Am J Epidemiol. 2016;184(8):555–69.CrossRefGoogle Scholar
  57. 57.
    Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, et al. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med. 2006;144(6):397–406.PubMedCrossRefGoogle Scholar
  58. 58.
    Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the Nurses’ Health Study. Obstet Gynecol. 2013;121(4):709–16.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Pilarski R, Buys SS, Farmer M, Khan S, Klein C, Kohlmann W, et al. NCCN guidelines index table of contents discussion NCCN guidelines version 1. 2018 Panel Members Genetic/Familial High-Risk Assessment: Breast and Ovarian. 2018.Google Scholar
  60. 60.
    Walker JL, Powell CB, Chen LM, Carter J, Bae Jump VL, Parker LP, et al. Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer. 2015;121:2108–20.PubMedCrossRefGoogle Scholar
  61. 61.
    Kang S, Yoo HJ, Hwang JH, Lim M-C, Seo S-S, Park S-Y. Sentinel lymph node biopsy in endometrial cancer: meta-analysis of 26 studies. Gynecol Oncol. 2011;123(3):522–7.PubMedCrossRefGoogle Scholar
  62. 62.
    Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100(1):58–64.PubMedCrossRefGoogle Scholar
  63. 63.
    Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80–7.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 2006;296(2):185.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Manchanda R, Menon U. Setting the threshold for surgical prevention in women at increased risk of ovarian cancer. Int J Gynecol Cancer. 2017;28(1):1.Google Scholar
  66. 66.
    Manchanda R, Legood R, Pearce L, Menon U. Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women. Gynecol Oncol. 2015;139(3):487–94.PubMedCrossRefGoogle Scholar
  67. 67.
    Manchanda R, Legood R, Antoniou AC, Gordeev VS, Menon U. Specifying the ovarian cancer risk threshold of “premenopausal risk-reducing salpingooophorectomy” for ovarian cancer prevention: a cost-effectiveness analysis. J Med Genet. 2016;53(9):591–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Kenkhuis MJA, de Bock GH, Oude Elferink P, Arts HJG, Oosterwijk JC, Jansen L, et al. Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers. Maturitas. 2010;66(3):310–4.PubMedCrossRefGoogle Scholar
  69. 69.
    Manchanda R, Abdelraheim A, Johnson M, Rosenthal AN, Benjamin E, Brunell C, et al. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG. 2011;118(7):814–24.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Finch A, Metcalfe KA, Chiang J, Elit L, McLaughlin J, Springate C, et al. The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psychooncology. 2013;22(1):212–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Madalinska JE, Hollenstein J, Bleiker E, Van Beurden M, Valdimarsdottir HB, Massuger LF, et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol. 2005;23(28):6890–8.PubMedCrossRefGoogle Scholar
  72. 72.
    Robson M, Hensley M, Barakat R, Brown C, Chi D, Poynor E, et al. Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol. 2003;89(2):281–7.PubMedCrossRefGoogle Scholar
  73. 73.
    Benshushan A, Rojansky N, Chaviv M, Arbel-Alon S, Benmeir A, Imbar T, et al. Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy. Climacteric. 2009;12(5):404–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Limouzin-Lamothe MA, Mairon N, Joyce CRB, Le Gal M. Quality of life after the menopause: influence of hormonal replacement therapy. Am J Obstet Gynecol. 1994;170(2):618–24.PubMedCrossRefGoogle Scholar
  75. 75.
    Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005;23(31):7804–10.PubMedCrossRefGoogle Scholar
  76. 76.
    Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst. 2008;100(19):1361–7.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol. 2004;22(6):1045–54.PubMedCrossRefGoogle Scholar
  78. 78.
    Marchetti C, Iadarola R, Palaia I, di Donato V, Perniola G, Muzii L, et al. Hormone therapy in oophorectomized BRCA1/2 mutation carriers. Menopause. 2014;21(7):763–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Birrer N, Chinchilla C, Del Carmen M, Dizon DS. Is hormone replacement therapy safe in women with a BRCA mutation? Am J Clin Oncol. 2016;41(3):313–5.Google Scholar
  80. 80.
    Madalinska JB, Van Beurden M, Bleiker EMA, Valdimarsdottir HB, Hollenstein J, Massuger LF, et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol. 2006;24(22):3576–82.PubMedCrossRefGoogle Scholar
  81. 81.
    Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer. 2008;8(1):155.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–30.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Gareth Evans D, Izatt L, Eeles RA, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Douglas F, Hodgson S, Walker L, Porteous ME, Morrison PJ, Side LE, John Kennedy M, Houghton C, Donaldson A, Rogers MT, Dorkins H, Miedzybrodzka Z, Gregory H, Eason J, Barwell J, McCann E, Murray A, Antoniou AC, Easton DF, EMBRACE. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812–22.  https://doi.org/10.1093/jnci/djt095.CrossRefPubMedGoogle Scholar
  84. 84.
    Coulet F, Fajac A, Colas C, Eyries M, Dion-Minière A, Rouzier R, et al. Germline RAD51C mutations in ovarian cancer susceptibility. Clin Genet. 2013;83(4):332–6.PubMedCrossRefGoogle Scholar
  85. 85.
    Pearce CL, Stram DO, Ness RB, Stram DA, Roman LD, Templeman C, et al. Population distribution of lifetime risk of ovarian cancer in the United States. Cancer Epidemiol Biomark Prev. 2015;24(4):671–6.CrossRefGoogle Scholar
  86. 86.
    Sutcliffe S, Pharoah PD, Easton DF, Ponder BA. Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer. Int J Cancer. 2000;87(1):110–7.PubMedCrossRefGoogle Scholar
  87. 87.
    Srivastava A, McKinnon W, Wood ME. Risk of breast and ovarian cancer in women with strong family histories. Oncology. 2001;15(7):889–902.PubMedGoogle Scholar
  88. 88.
    Jervis S, Song H, Lee A, Dicks E, Tyrer J, Harrington P, et al. Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. J Med Genet. 2014;51(2):108–13.PubMedCrossRefGoogle Scholar
  89. 89.
    Jervis S, Song H, Lee A, Dicks E, Harrington P, Baynes C, et al. A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects. J Med Genet. 2015;52(7):465–75.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Siyam T, Ross S, Campbell S, Eurich DT, Yuksel N. The effect of hormone therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic review. BMC Womens Health. 2017;17:22.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Parker WH, Feskanich D, Broder M, Chang E, Shoupe D, Farquhar C, et al. Long-term mortalilty associated with oophorectomy versus ovarian conservation in the Nurses’ Health Study. Obstet Gynecol. 2013;121(4):709–16.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 2006;7(10):821–8.PubMedCrossRefGoogle Scholar
  93. 93.
    Evans EC, Matteson KA, Orejuela FJ, Alperin M, Balk EM, El-Nashar S, et al. Salpingo-oophorectomy at the time of benign hysterectomy: a systematic review. Obstet Gynecol. 2016;128:476–85.PubMedCrossRefGoogle Scholar
  94. 94.
    Lancaster JM, Powell CB, Chen LM, Richardson DL. Society of gynecologic oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015;136(1):3–7.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Committee on Gynecologic Practice. Committee opinion no. 620: salpingectomy for ovarian cancer prevention. Obstet Gynecol. 2015;125(1):279–81.CrossRefGoogle Scholar
  96. 96.
    Falconer H, Yin L, Grönberg H, Altman D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst. 2015;107(2):dju410.PubMedCrossRefGoogle Scholar
  97. 97.
    Kwon JS, Mcalpine JN, Hanley GE, Finlayson SJ, Cohen T, Miller DM, et al. Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy. Obstet Gynecol. 2015;125(2):338–45.PubMedCrossRefGoogle Scholar
  98. 98.
    Minig L, Chuang L, Patrono MG, Cárdenas-Rebollo JM, García-Donas J. Surgical outcomes and complications of prophylactic salpingectomy at the time of benign hysterectomy in premenopausal women. J Minim Invasive Gynecol. 2015;22(4):653–7.PubMedCrossRefGoogle Scholar
  99. 99.
    Morelli M, Venturella R, Mocciaro R, Di Cello A, Rania E, Lico D, et al. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere. Gynecol Oncol. 2013;129(3):448–51.PubMedCrossRefGoogle Scholar
  100. 100.
    Findley AD, Siedhoff MT, Hobbs KA, Steege JF, Carey ET, McCall CA, et al. Short-term effects of salpingectomy during laparoscopic hysterectomy on ovarian reserve: a pilot randomized controlled trial. Fertil Steril. 2013;100(6):1704–8.PubMedCrossRefGoogle Scholar
  101. 101.
    Ni L, Sadiq S, Mao Y, Cui Y, Wang W, Liu J. Influence of various tubal surgeries to serum antimullerian hormone level and outcome of the subsequent IVF-ET treatment. Gynecol Endocrinol. 2013;29(4):345–9.PubMedCrossRefGoogle Scholar
  102. 102.
    Ye X, Yang Y, Sun X. A retrospective analysis of the effect of salpingectomy on serum antiMüllerian hormone level and ovarian reserve. Am J Obstet Gynecol. 2015;212(1):e53.e1–e53.e10.CrossRefGoogle Scholar
  103. 103.
    Vorwergk J, Radosa MP, Nicolaus K, Baus N, Jimenez Cruz J, Rengsberger M, et al. Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate. J Cancer Res Clin Oncol. 2014;140(5):859–65.PubMedCrossRefGoogle Scholar
  104. 104.
    ClinicalTrials.gov identifier (NCT number): NCT01907789. Prophylactic salpingectomy with delayed oophorectomy, risk-reducing salpingo-oophorectomy, and ovarian cancer screening among BRCA mutation carriers: a proof-of-concept study.
  105. 105.
    M.D. Anderson Cancer Center. The women choosing surgical prevention (WISP) trial - Full Text View - ClinicalTrials.gov. ClinicalTrials.gov Identifier: NCT02760849.
  106. 106.
    Harmsen MG, Arts-de Jong M, Hoogerbrugge N, Maas AHEM, Prins JB, Bulten J, et al. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. BMC Cancer. 2015;15(1):593.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Leblanc E, Narducci F, Farre I, Peyrat J-P, Taieb S, Adenis C, et al. Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development. Gynecol Oncol. 2011;121(3):472–6.PubMedCrossRefGoogle Scholar
  108. 108.
    Centre Oscar Lambret. Radical fimbriectomy for young BRCA mutation carriers - FullText View - ClinicalTrials.gov. ClinicalTrials.gov Identifier: NCT01608074.
  109. 109.
    Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol. 2013;121(1):14–24.PubMedCrossRefGoogle Scholar
  110. 110.
    Rice MS, Murphy MA, Vitonis AF, Cramer DW, Titus LJ, Tworoger SS, et al. Tubal ligation, hysterectomy and epithelial ovarian cancer in the New England Case-Control Study. Acta Obstet Gynecol Scand. 2013;133(10):86–94.Google Scholar
  111. 111.
    Rice MS, Hankinson SE, Tworoger SS. Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the Nurses’ Health Studies. Fertil Steril. 2014;102(1):192.e3–8.e3.CrossRefGoogle Scholar
  112. 112.
    Lessard-Anderson CR, Handlogten KS, Molitor RJ, Dowdy SC, Cliby WA, Weaver AL, et al. Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma. Gynecol Oncol. 2014;135:423–7.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Madsen C, Baandrup L, Dehlendorff C, Kjaer SK. Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study. Acta Obstet Gynecol Scand. 2015;94(1):86–94.PubMedCrossRefGoogle Scholar
  114. 114.
    Gaitskell K, Green J, Pirie K, Reeves G. Tubal ligation and ovarian cancer risk in a large cohort: substantial variation by histological type. Int J Cancer. 2016;138(5):1076–84.PubMedCrossRefGoogle Scholar
  115. 115.
    Cibula D, Widschwendter M, Májek O, Dusek L. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update. 2011;17:55–67.CrossRefGoogle Scholar
  116. 116.
    Rice MS, Murphy MA, Tworoger SS. Tubal ligation, hysterectomy and ovarian cancer: a meta-analysis. J Ovarian Res. 2012;5(1):13.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Chan J, Sammel MD, Friebel TM, Gracia C, Rebbeck TR. Tubal ligation does not modify ovarian cancer risk in BRCA mutation carriers. Fertil Steril. 2015;104(3):e259.CrossRefGoogle Scholar
  118. 118.
    Beral V, Doll R, Hermon C, Peto R, Reeves G, Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371(9609):303–14.PubMedCrossRefGoogle Scholar
  119. 119.
    Franceschi S, Parazzini F, Negri E, Booth M, La Vecchia C, Beral V, et al. Pooled analysis of 3 european case-control studies of epithelial ovarian cancer: III. Oral contraceptive use. Int J Cancer. 1991;49(1):61–5.CrossRefGoogle Scholar
  120. 120.
    Bosetti C, Negri E, Trichopoulos D, Franceschi S, Beral V, Tzonou A, et al. Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer. 2002;102(3):262–5.PubMedCrossRefGoogle Scholar
  121. 121.
    Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol. 2013;122:139–47.PubMedCrossRefGoogle Scholar
  122. 122.
    Cibula D, Zikan M, Dusek L, Majek O. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther. 2011;11(8):1197–207.PubMedCrossRefGoogle Scholar
  123. 123.
    Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013;31(33):4188–98.PubMedCrossRefGoogle Scholar
  124. 124.
    Stine JE, Bae-Jump V. Metformin and gynecologic cancers. Obstet Gynecol Surv. 2014;69(8):477–89.PubMedCrossRefGoogle Scholar
  125. 125.
    Gadducci A, Biglia N, Tana R, Cosio S, Gallo M. Metformin use and gynecological cancers: a novel treatment option emerging from drug repositioning. Crit Rev Oncol Hematol. 2016;105:73–83.PubMedCrossRefGoogle Scholar
  126. 126.
    Rattan R, Giri S, Hartmann LC, Shridhar V. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med. 2011;15(1):166–78.PubMedCrossRefGoogle Scholar
  127. 127.
    Li C, Liu VWS, Chan DW, Yao KM, Ngan HYS. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells. Int J Gynecol Cancer. 2012;22(1):15–22.PubMedCrossRefGoogle Scholar
  128. 128.
    Al-Wahab Z, Mert I, Tebbe C, Chhina J, Hijaz M, Morris RT, et al. Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: similarity with calorie restriction. Oncotarget. 2015;6(13):10908–23.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Algire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene. 2011;30(10):174–82.CrossRefGoogle Scholar
  130. 130.
    Trabert B, Ness RB, Lo-Ciganic W-H, Murphy MA, Goode EL, Poole EM, et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst. 2014;106(2):djt431.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Baandrup L, Faber MT, Christensen J, Jensen A, Andersen KK, Friis S, et al. Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Acta Obstet Gynecol Scand. 2013;92(3):245–55.PubMedCrossRefGoogle Scholar
  132. 132.
    Baandrup L. Drugs with potential chemopreventive properties in relation to epithelial ovarian cancer--a nationwide case-control study. Dan Med J. 2015;62(7):B5117.PubMedGoogle Scholar
  133. 133.
    Tsoref D, Panzarella T, Oza A. Aspirin in prevention of ovarian cancer: are we at the tipping point? J Natl Cancer Inst. 2014;106(2):djt453.PubMedCrossRefGoogle Scholar
  134. 134.
    Olsen CM, Green AC, Whiteman DC, Sadeghi S, Kolahdooz F, Webb PM. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer. 2007;43(4):690–709.PubMedCrossRefGoogle Scholar
  135. 135.
    Zhang M, Xie X, Lee AH, Binns CW. Sedentary behaviours and epithelial ovarian cancer risk. Cancer Causes Control. 2004;15(1):83–9.PubMedCrossRefGoogle Scholar
  136. 136.
    Poorolajal J, Jenabi E, Masoumi SZ. Body mass index effects on risk of ovarian cancer: a meta- analysis. Asian Pac J Cancer Prev. 2014;15(18):7665–71.PubMedCrossRefGoogle Scholar
  137. 137.
    Gwinn ML, Lee NC, Rhodes PH, Layde PM, Rubin GL. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol. 1990;43(6):559–68.PubMedCrossRefGoogle Scholar
  138. 138.
    Whiteman DC, Siskind V, Purdie DM, Green AC. Timing of pregnancy and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomark Prev. 2003;12(1):42–6.Google Scholar
  139. 139.
    Jordan SJ, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA. Breast-feeding and risk of epithelial ovarian cancer. Cancer Causes Control. 2012;23(6):919–27.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Sarika Gupta
    • 1
  • Sarfraz Ahmad
    • 2
    • 3
  • Lorna A. Brudie
    • 4
  1. 1.Department of GynecologyIndraprastha Apollo HospitalNew DelhiIndia
  2. 2.Department of Gynecologic OncologyFlorida Hospital (AdventHealth) Cancer Institute, Florida State UniversityOrlandoUSA
  3. 3.Department of Gynecologic Oncology, Colleges of MedicineUniversity of Central Florida, and Florida State UniversityOrlandoUSA
  4. 4.Department of Gynecologic OncologyOrlando Health UF Health Cancer CenterOrlandoUSA

Personalised recommendations